OncoMatch/Clinical Trials/NCT04126876
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
Is NCT04126876 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Tilsotolimod and Saline (0.9% sodium chloride) for malignant melanoma.
Treatment: Tilsotolimod · Saline (0.9% sodium chloride) — Currently, there is no widely used adjuvant treatment available to improve survival after surgical excision of a primary melanoma. In a previous study, loco-regional and systemic immune stimulations, as well as favourable clinical outcomes in terms of sentinel lymph node (SLN) tumor status and recurrence-free survival (RFS) in patients with clinical stage I-II melanoma who received a low dose of toll-like receptor 9 (TLR-9) CPG7909 (CpG-B ODN) intradermally at the excision site of the primary tumor prior to SLN biopsy (SNB) were described. In this phase II trial the investigators had investigated the clinical activity of a next-generation CpG-ODN, IMO-2125, and it's ability to induce loco-regional and systemic immune stimulation in pT3-4 cN0M0 melanoma patients who are scheduled to undergo a combined re-excision and SNB is
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Disease stage
Required: Stage PT3, PT4 (pathological tumor stage (pT))
pathological tumor stage (p) T3-4 cN0M0
Performance status
WHO 0–1
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04126876 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage PT3 or PT4 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages